Sep 10, 8:01 PM
The Illusion of the Swiss Medtech Boom
Record revenues obscure a mounting exodus of jobs and capital from Switzerland.
On paper, the Swiss medical technology industry looks invincible. A record turnover of 26 billion Swiss francs in 2025 and a trade surplus exceeding 5 billion francs suggest a sector in prime condition. Yet beneath these comfortable figures, the foundation of Switzerland’s industrial pride is cracking.
The announcement from Zimmer Biomet provided a blunt reality check. The joint prosthesis manufacturer plans to eliminate up to 580 of its 730 positions at its site in Winterthur. For a sector employing roughly 72,000 people across 1,400 companies, such a drastic reduction is no statistical anomaly. It confirms what Swiss Medtech, the industry association, reported in its latest biennial assessment: net job creation has plummeted to a mere 200 positions, a fraction of the ten-year average of 1,500.
More alarming still is the capital freeze. An unprecedented 43 percent of surveyed companies plan no domestic investments whatsoever. Swiss Medtech Director Adrian Hunn observed that investments are the jobs of tomorrow. When nearly half the sector refuses to commit fresh capital, tomorrow looks decidedly bleak. Damian Müller, President of Swiss Medtech and FDP Councillor of States, echoed this concern, calling the planned cuts in Winterthur extremely worrying.
The causes of this retreat are predictable. A perpetually strong franc renders Swiss exports expensive, while domestic labor costs and administrative burdens weigh down margins. Yet the structural damage runs deeper, exacerbated by trade barriers and regulatory friction. Ever since 2021, when mutual recognition of medical device certifications with the European Union lapsed, Swiss manufacturers have been forced to navigate a labyrinth of double bureaucracy. That single administrative barrier drains between 150 and 200 million francs annually from Swiss firms.
Faced with high domestic taxes, administrative hurdles, and US trade tariffs, companies are acting rationally by relocating. Firms like Burgdorf-based Ypsomed, headed by Simon Michel, are expanding production abroad—in Germany, China, and soon the United States—to remain close to their primary pharmaceutical clients.
If Switzerland expects to retain high-tech manufacturing, its political leadership cannot rely on past prestige. Industry representatives are now calling for deregulation, lower tax burdens, and a unilateral recognition of US medical approvals to restore competitiveness. Without a swift reduction in domestic red tape, Switzerland risks watching its most profitable exporters gradually shift their future elsewhere.
Written by Andreas Hofer andreas.hofer@alpineweekly.com
